IMU Biosciences's $53M+: Decoding the Immune System at Scale
UK biotech IMU Biosciences extended its oversubscribed Series A past $53M in June 2026 to map and decode the human immune system for drug discovery.
2026 venture capital activity reflects a market balancing AI infrastructure bets, selective growth equity, and renewed interest in capital-efficient startups. Our coverage tracks the rounds, fund launches, and strategic shifts that matter for founders and investors.
Read the latest 2026 VC news and funding roundups below.
UK biotech IMU Biosciences extended its oversubscribed Series A past $53M in June 2026 to map and decode the human immune system for drug discovery.
Barcelona biopharma Ona Therapeutics closed an oversubscribed $86.6M Series B in June 2026 to advance first-in-class antibody-drug conjugates for resistant cancers.
UK healthcare-tech company Semble raised a £30M Series C led by Revaia in June 2026, scaling its practice-management platform for clinicians.
Edinburgh legal-AI startup Wordsmith raised a $70M Series B in June 2026, backed by Highland Europe and Index Ventures, reaching $100M in total funding.
Aippy, built by NADA AI, raised tens of millions at a $250M valuation in June 2026 to build the first AI-native game community — Asia's answer to AI entertainment.
Ex-Meta CTO Mike Schroepfer's Gigascale Capital closed its first institutional fund at $250M in June 2026 to back energy, materials, and grid infrastructure.